Literature DB >> 26691539

Upper neck papillary thyroid cancer (UPTC): A new proposed term for the composite of thyroglossal duct cyst-associated papillary thyroid cancer, pyramidal lobe papillary thyroid cancer, and Delphian node papillary thyroid cancer metastasis.

Marica Zizic1, William Faquin2, Antonia E Stephen3, Dipti Kamani1, Romy Nehme1, Cristian M Slough1, Gregory W Randolph1,3.   

Abstract

OBJECTIVES/HYPOTHESIS: Thyroglossal duct cyst (TGDC) is a common congenital anomaly, but TGDC carcinoma is rare. Thyroglossal duct cyst carcinoma management is controversial, especially that of the orthotopic thyroid gland. We aim to provide an insight into the pathologic basis of this management controversy through the review of 28 TGDC cancer cases, thus far the largest such series to our knowledge. STUDY
DESIGN: Retrospective.
METHODS: Twenty-eight cases recorded as TGDC cancer in the hospital database were reviewed; their initial clinical diagnosis from medical chart review (DX1) and final pathological review diagnosis (DX2) through pathology slides review by our pathologist (blinded to DX1) were compared. The thyroid gland management and pathology were evaluated.
RESULTS: In the 28 TGDC carcinoma (hospital-recorded diagnosis) patients, DX1 and DX2 were respectively reported as 53% and 14% TGDC carcinoma, 11% and 29% as pyramidal lobe primary, and 4% and 25% as metastatic Delphian node. Thirty-two percent of cases were in the indeterminate category, in both DX1 and DX2, but included different patients. Thyroidectomy was performed in 54% of the cases, papillary thyroid cancer (PTC) was reported in 37% of these thyroid glands. Concurrent thyroid gland malignancy was reported in all Delphian node and pyramidal lobe PTC patients.
CONCLUSION: The diagnosis of TGDC cancer comprises a heterogeneous group that includes true TGDC cancer, pyramidal lobe primary, Delphian node metastasis, and indeterminate cases. We propose a new terminology of upper neck papillary thyroid carcinoma (UPTC) to denote this heterogeneous group and recommend a rational algorithm for management. Correct pathologic subcategory and thyroid ultrasonography are essential for optimal management of thyroid gland in UPTC cases. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:1709-1714, 2016.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Delphian node metastasis; Thyroglossal duct cyst cancer; midline neck mass; pyramidal lobe PTC

Mesh:

Year:  2015        PMID: 26691539     DOI: 10.1002/lary.25824

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  A Clinicopathologic Series of 685 Thyroglossal Duct Remnant Cysts.

Authors:  Lester D R Thompson; Hannah B Herrera; Sean K Lau
Journal:  Head Neck Pathol       Date:  2016-05-09

2.  Thyroglossal Duct Cyst Carcinomas: A Clinicopathologic Series of 22 Cases with Staging Recommendations.

Authors:  Lester D R Thompson; Hannah B Herrera; Sean K Lau
Journal:  Head Neck Pathol       Date:  2016-10-04

3.  Imaging characteristics and findings in thyroglossal duct cyst cancer and concurrent thyroid cancer.

Authors:  Larry Shemen; Craig Harvey Sherman; Alyssa Yurovitsky
Journal:  BMJ Case Rep       Date:  2016-04-20

4.  Clinical characteristics of papillary thyroid carcinoma arising from the pyramidal lobe.

Authors:  Sang Gab Yoon; Jin Wook Yi; Chan-Yong Seong; Jong-Kyu Kim; Su-Jin Kim; Young Jun Chai; June Young Choi; Kyu Eun Lee
Journal:  Ann Surg Treat Res       Date:  2017-02-24       Impact factor: 1.859

Review 5.  Recurrence of papillary thyroid carcinoma from the residual pyramidal lobe: a case report and literature review.

Authors:  Mingjun Wang; Xiuhe Zou; Zhihui Li; Jingqiang Zhu
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

6.  Ultrasound for the detection of the pyramidal lobe of the thyroid gland.

Authors:  A Freilinger; K Kaserer; G Zettinig; P Pruidze; L F Reissig; T Rossmann; W J Weninger; S Meng
Journal:  J Endocrinol Invest       Date:  2022-02-14       Impact factor: 5.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.